Leserbrief
Letter: Dupilumab-Induced Facial Redness: Reported Outcomes after Switching to Tralokinumab
Dermatitis® · 15.06.2026
DOI: 10.1177/17103568261461069 ↗Kurz gefasst
Leserbrief in der Zeitschrift Dermatitis®, online erschienen am 15.06.2026. Verfasst von Shabnam Afzal und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of California Davis School of Medicine, Sacramento, California, USA. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- University of California Davis School of Medicine, Sacramento, California, USA.
- University of Michigan Medical School, Ann Arbor, Michigan, USA.
- Anne Arundel Dermatology, McLean, Virginia, USA.
Zitieren
APA
Afzal, S., Fayyad, D., & Hussain, A. N. (2026). Letter: Dupilumab-Induced Facial Redness: Reported Outcomes after Switching to Tralokinumab. Dermatitis®. https://doi.org/10.1177/17103568261461069
Vancouver
Afzal S, Fayyad D, Hussain AN. Letter: Dupilumab-Induced Facial Redness: Reported Outcomes after Switching to Tralokinumab. Dermatitis®. 2026. doi:10.1177/17103568261461069
BibTeX
@article{Afzal2026,
author = {Afzal, Shabnam and Fayyad, Deena and Hussain, Aamir N},
title = {Letter: Dupilumab-Induced Facial Redness: Reported Outcomes after Switching to Tralokinumab},
journal = {Dermatitis®},
year = {2026},
doi = {10.1177/17103568261461069}
}
EUVIMED